Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555448 · ClinicalTrials.gov registry record · Phase 4
Once Daily Immunosuppression Regimen
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT03555448 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 51 participants.
The verdict
NCT03555448, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether an immunosuppressive maintenance regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is associated with better compliance, tolerability, and lower biopsy proven rejection.
Interventions
- DRUG Once daily immunosuppression regimen
- DRUG Twice daily immunosuppression regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2023-11-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03555448
The ClinicalTrials.gov registry entry for NCT03555448 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Once daily immunosuppression regimen is the first listed.
NCT03555448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03555448 about?
NCT03555448 is a clinical study titled "Once Daily Immunosuppression Regimen". The purpose of this research study is to determine whether an immunosuppressive maintenance regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is associated with better compliance, tolerability, and lower biopsy proven rejection.
What is the current status of trial NCT03555448?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2018-06-04. Estimated completion is 2023-11-10.
What interventions are being tested in trial NCT03555448?
The interventions under investigation include: Once daily immunosuppression regimen (DRUG), Twice daily immunosuppression regimen (DRUG).
Who is sponsoring clinical trial NCT03555448?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.